Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Intrahepatic cholestasis
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 14 Feb 2019 Status changed from active, no longer recruiting to completed.
- 22 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 14 May 2014 New trial record